TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 3 years and above on the day of enrollment~* For subjects aged 3 to 18 years: Informed consent form has been signed and dated by the parent or other legally acceptable representative.~* For subjects 19 years and above: Informed consent form has been signed and dated by the subject.~* Receipt of one dose of VaxigripTetra inj. (on the day of inclusion) as part of routine clinical practice according to the approved local product insert~Exclusion Criteria:~- Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in a clinical study investigating a vaccine, drug, medical device, or medical procedure

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Naturally postmenopausal women of any age with at least one ovary~* Diagnosis of Hypoactive Sexual Desire Disorder, generalized acquired type,of at least six months duration~* Stable, monogamous heterosexual relationship for at least one year~* Willing to discuss sexual issues~* Willing to engage in sexual activity at least once a month~* Normal Pap smear~* Normal mammogram~* Normal uterine lining~* Able to comply with daily use of handheld data entry device~Exclusion criteria:~* Sexual dysfunctions other than HSDD, such as Sexual Aversion Disorder, Substance-induced Sexual Dysfunction, Dyspareunia, Vaginismus, Gender Identity Disorder, Paraphilia and Sexual Dysfunction due to a General Medical Condition~* Partner with inadequately treated organic or psychosexual dysfunction~* Sexual function impaired by psychiatric disorder~* Sexual function impaired by gynecological disorder~* Major Depression~* Suicidal behavior or ideation~* Major life stress that could impair sexual function~* Substance abuse

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- flibanserin 100mg (Type: EXPERIMENTAL): flibanserin 100mg po qd
- placebo (Type: PLACEBO_COMPARATOR): placebo one tablet po qd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Good physical health~* Has never had Papanicolaou testing (Pap, cervical or anal) or has only had normal Pap test results~* Other inclusion criteria will be discussed with the investigator~Exclusion Criteria:~* History of severe allergic reaction that required medical intervention~* Currently enrolled in a clinical trial~* If participant is female, pregnant~* Currently immunocompromised or having received immunosuppressive therapy in the last year~* Positive test for HPV~* History of HPV-related external genital lesions or HPV-related anal lesions or anal cancer~* If participant is female, history of abnormal cervical biopsy results~* Other exclusion criteria will be discussed with the investigator

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- Females (Type: ACTIVE_COMPARATOR): Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
- Heterosexual Males (Type: EXPERIMENTAL): Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
- Men who have Sex with Men (Type: EXPERIMENTAL): Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Intravenous Thrombolysis for Wake-up Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected acute ischemic stroke that occurred during sleep or patients who wake up with focal neurological symptoms. This includes all patients who were last known to be neurologically normal the night before,but then found upon awakening with stroke deficits. It will be considered that the last known onset time is the time when the patient was last known to be well.~* 18 to 80 years old~* NIHSS (National Institutes of Health Stroke Scale) ≤25~* Blood Pressure ≤185 mmHg systolic \& ≤110 mmHg diastolic at the time of enrollment.~Treatment of higher systolic BP is permitted, prior to enrollment~* IV t-PA must be given within 3 hours of awakening from sleep~* Female patients of child-bearing potential must have a negative pregnancy test prior to enrollment~Exclusion Criteria:~* CT Exclusion Criteria: Hypodensity \>1/3 middle cerebral artery (MCA) territory on non-contrast cranial CT scan or evidence of intracranial or subarachnoid hemorrhage~* Prior ischemic stroke within 3 months of the presenting event~* History of intracranial hemorrhage~* Known secured or unsecured cerebral aneurysm or vascular malformation~* Inability to control systolic BP \> 185 mmHg or diastolic BP \> 110 mmHg with IV anti-hypertensive medications~* Known coagulopathy or evidence of active bleeding~* Surgical procedures, biopsy, subclavian venous or arterial puncture, trauma within 14 days of the event~* Gastrointestinal or genitourinary bleeding within 14 days of the event~* Treated with IV heparin within the previous 24 hours \& an abnormal (partial thromboplastin time) PTT~* Oral anticoagulants \& an (international normalized ratio) INR \>1.7~* Platelet count \<100,000~* Venous glucose either \<50 or \>450~* Any patient who qualifies for this protocol should not be treated with (intra-arterial therapy) IAT If the treating physician believes a patient should undergo IAT, those patients should be identified a priori and not enrolled into this protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- off label rt-PA used (Type: EXPERIMENTAL): off label rt-PA used on all subject enrolled within 3 hours of waking with stroke symptoms at the standard of care dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight or obese adults (age ≥45 yrs and BMI ≥25 kg/m2)~* prediabetes and OSA (AHI ≥ 5)~* regular life styles and schedules (no shift work in the past 6 months, no travel across time zones during the past 4 weeks)~* habitual bedtimes of at least 6 hours but not exceeding 9 hours will be eligible.~* not to take any medications during the study period with the exception of antihypertensives and lipid lowering agents~* not on hormone replacement therapy.~* have sedentary activities and no competitive athletes or subjects with high exercise levels.~Exclusion Criteria:~* previous or current treatment with supplemental oxygen~* requirement of supplemental oxygen or bi-level positive airway pressure for OSA treatment during titration~* presence of active infection, psychiatric disease or history of other significant illness (e.g., myocardial infarction, congestive heart failure, stroke, arrhythmia, chronic kidney or liver disease0~* clinical depression as evidenced by a score \>16 in CES-D scale~* smoking, or routine alcohol use (more than 2 drinks per day), or excessive caffeine intake (\>300mg per day)

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Continuous positive airway pressure (Type: ACTIVE_COMPARATOR): 2 weeks of continuous positive airway pressure (CPAP) treatment which includes wearing the CPAP mask for 8 hours each night
- Placebo (Type: PLACEBO_COMPARATOR): 2 weeks of oral administration of a placebo tablet 30min before bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* history of asthma for ≥ 6 months~* taking inhaled corticosteroids~* non-smoking~* Baseline (pre-bronchodilator) FEV1 35-80% predicted at screening.~* Reversible airways disease as indicated by an increase of FEV1 ≥12% from baseline after nebulised salbutamol or albuterol.~* symptomatic according to the ACQ-7~Exclusion Criteria:~* Unstable severe asthma~* Recent respiratory illness~* Presence of other respiratory disease or chronic pulmonary condition other than asthma~* Treatment with omalizumab within 4 months of study~* Recent gastrointestinal or respiratory parasitic infestation~* History of severe allergy to food or drugs~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GSK679586 (Type: EXPERIMENTAL): Subjects will receive three, once monthly intravenous administration of 10 mg/kg of GSK679586, according to randomization
- PLACEBO (Type: PLACEBO_COMPARATOR): Subjects will receive three, once monthly intravenous administration of saline, according to randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients age 40 years or more~* Diagnosis of Chronic Obstructive Lung Disease (COPD) (moderate to severe as classified by the Global Initiative for COPD (GOLD) Guidelines, 2008~* Smoking history of at least 10 pack-years~* Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) \<80% and ≥30% of the predicted normal value~* Post-bronchodilator FEV1/Forced Vital Capacity (FVC) \<0.7~* Symptomatic patients, according to daily electronic diary data between visit 2 (Day -8) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to visit 3~Exclusion Criteria:~* Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to the first visit~* Patients who have had a respiratory tract infection within 4 weeks prior to the first visit~* Patients with concomitant pulmonary disease~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular co-morbid conditions~* Patients with a history of asthma or a blood eosinophil count \>600/mm3 or onset of symptoms prior to 40 years~* Patients with eczema, known high IgE levels or a known positive skin prick test~* Patients participating in the active phase of a pulmonary rehabilitation programme~* Patients contraindicated for the treatment with anticholinergics, long and short-acting beta-2 agonists or sympathomimetic amines~* Patients with a history of alpha-1 anti-trypsin deficiency~* Patients on long term oxygen therapy (\>15hr per day)~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 12.5 µg q.d. (Type: EXPERIMENTAL): NVA237 12.5 µg once daily
- NVA237 25.0 µg q.d. (Type: EXPERIMENTAL): NVA237 25.0 µg once daily
- NVA237 12.5 µg b.i.d. (Type: EXPERIMENTAL): NVA237 12.5 µg twice daily
- NVA237 50.0 µg q.d. (Type: EXPERIMENTAL): NVA237 50.0 µg once daily
- NVA237 25.0 µg b.i.d. (Type: EXPERIMENTAL): NVA237 25.0 µg twice daily
- NVA237 100.0 µg q.d. (Type: EXPERIMENTAL): NVA237 100.0 µg once daily
- NVA237 50.0 µg b.i.d. (Type: EXPERIMENTAL): NVA237 50.0 µg twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to NVA237 once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radial Artery Access With Ultrasound Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients presenting for cardiac or peripheral catheterization with planned radial approach.~* Barbeau's or Allen's test indicating at least some degree of collateral circulation in palmar vessels~* Functional ultrasound equipment with ultrasound trained attending operator~Exclusion Criteria:~* Inability to provide informed consent~* Femoral access~* Emergency procedure (Shock, STEMI)~* End-stage renal disease on hemodialysis~* Previous ipsilateral puncture within 1 week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palpation (Type: ACTIVE_COMPARATOR): Manual palpation of radial pulse, as sole guide to needle cannulation.
- Ultrasound (Type: EXPERIMENTAL): Real-time ultrasound guidance to facilitate needle cannulation of artery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, ages 18-79 years, inclusive~* Fasting, untreated non-high-density lipoprotein cholesterol (non-HDL-C) level above NCEP ATPIII goals~* Fasting, untreated triglyceride (TG) level in the high to very high range~* Provide written informed consent and authorization for protected health information disclosure~Exclusion Criteria:~* Pregnancy~* Use of lipid-altering drugs which cannot be stopped~* History of certain cardiovascular conditions or cardiac surgery within prior 6 months~* Body mass index above 40 kg per square meter~* Allergy or sensitivity to omega-3 fatty acids or to statin drugs~* Poorly-controlled conditions including diabetes, hypertension, or thyroid disease~* Certain muscle, liver, kidney, lung, or gastrointestinal conditions~* Certain medications~* Active cancers treated within prior 2 years (except non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- atorvastatin arm (Type: ACTIVE_COMPARATOR): atorvastatin + placebo
- Lovaza arm (Type: EXPERIMENTAL): Lovaza + atorvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Diagnosis of rheumatoid arthritis for at least 6 months~* Be on a stable dose of methotrexate for 4 weeks~* Have at least 4 swollen and 4 tender joints~Exclusion Criteria:~* Prior exposure to biologic anti-TNFalpha agents~* Inflammatory diseases other than rheumatoid arthritis~* Treatment with Disease Modifying Anti-rheumatic drug (DMARDs)/systemic immunosuppressives other than methotrexate during the 4 weeks prior to the first administration of study agent~* History of, or ongoing, chronic or recurrent infectious disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Golimumab + methotrexate (MTX) (Type: EXPERIMENTAL): Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
- Placebo + methotrexate (MTX) (Type: EXPERIMENTAL): Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 21-64~* Assigned a female sex at birth and now self-identifies as a man, trans masculine, trans man, FTM, transgender, genderqueer/non-binary, transsexual, male, and/or another diverse transgender identity or expression~* Have a cervix~* Sexually active in the past 36 months (with sexual partner(s) of any gender)~* Able to speak and understand English~* Willing and able to provide informed consent~Exclusion Criteria:~* Unable to provide informed consent due to severe mental or physical illness~* Substance intoxication at the time of interview

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with Ph+ CML-CP within 3 months of diagnosis. Male or female patients' ≥ 18 years of age. Patients must have adequate end organ function.~Exclusion Criteria:~Previously documented T315I mutation. Other CML treatment is an exclusion criteria with the following exception: While awaiting study start, patients may be treated with anagrelide (no treatment duration limit), hydroxyurea (no treatment duration limit), and/or up to a 14 day supply of a tyrosine kinase inhibitor (TKI) approved by the FDA for frontline treatment. Patients taking a TKI prior to study entry must have at least a one day washout from their last dose of medication and have recovered from any side effects of such therapy.~Impaired cardiac function as defined by the protocol. Patients with contraindications to receiving nilotinib, including concomitant medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete